Bungaro Maristella, Passiglia Francesco, Scagliotti Giorgio V
Department of Oncology, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.
Biomedicines. 2022 Mar 26;10(4):776. doi: 10.3390/biomedicines10040776.
Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse survival outcomes compared to the general population. The world's leading professional organizations provided new recommendations for the diagnosis, treatment, and follow-up of lung cancer patients during the pandemic as a guide for prioritizing cancer care issues. Telemedicine was preferred for non-urgent consultations, and screening programs were temporarily suspended, leading to possible diagnostic delays along with an estimated increase in cause-specific mortality. A vaccine campaign has recently emerged as the main weapon to fight the COVID-19 pandemic, inverting this negative trend. This work aims to provide a comprehensive overview of the epidemiology and immune-pathophysiology of SARS-CoV-2 infection in cancer patients, highlighting the most relevant changes in the clinical management of lung cancer patients during the pandemic.
与普通人群相比，肺癌患者感染新冠病毒、出现肺部并发症及生存结局较差的风险更高。全球主要专业组织针对大流行期间肺癌患者的诊断、治疗及随访提供了新建议，作为优先处理癌症护理问题的指导。非紧急会诊首选远程医疗，筛查项目暂时中止，这可能导致诊断延迟，并估计特定病因死亡率会上升。最近，疫苗接种运动已成为抗击新冠疫情的主要武器，扭转了这一消极趋势。这项工作旨在全面概述癌症患者中新冠病毒感染的流行病学和免疫病理生理学，突出大流行期间肺癌患者临床管理中最相关的变化。
